Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

PXL770, a first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK), is a clinical-stage drug candidate targeting the underlying mechanisms of autosomal dominant polycystic kidney